2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

treatment (tx) for metastatic colorectal cancer (mCRC): efficacy by skin
toxicity. J Clin Oncol. 2010;28 (suppl; abstr 3528).
8. Tejpar, S, et al. Phase I/II study of cetuximab dose-escalation in patients
with metastatic colorectal cancer (mCRC) with no or slight skin reactions on
cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK),
Pharmacodynamic (PD) and efficacy data. J Clin Oncol. 2007;25 (suppl; abstr
4037).
9. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a
predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in
colon cancer. J Clin Oncol. 2010;28:3219-3226.
10. O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor
gene expression and recurrence in four independent studies of patients with
stage II/III colon cancer treated with surgery alone or surgery plus adjuvant
fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937-3944.
11. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative
multigene reverse transcriptase-polymerase chain reaction assay for assessment
of recurrence risk in patients with stage II colon cancer. J Clin Oncol.
2011;29:4611-4619.
12. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of
epiregulin and amphiregulin and K-ras mutation status predict disease
control in metastatic colorectal cancer patients treated with cetuximab. J Clin
Oncol. 2007;25:3230-3237.
13. Tejpar S, De Roock W, Biesmans B, et al. High amphiregulin and
epiregulin expression in KRAS wild-type colorectal primaries predicts response
and survival benefit after treatment with cetuximab and irinotecan for
metastatic disease. Presented at: 2008 Gastrointestinal Cancers Symposium;
January 2010; Orlando, FL.
14. Jonker DH, Karapetis C, Harbison C, et al. High epiregulin (EREG)
gene expression plus K-ras wild-type (WT) status aspredictors of cetuximab
benefit in the treatment of advanced colorectal cancer (ACRC): results from
NCIC CTG CO. 17—a phase III trial of cetuximab versus best supportive care
(BSC). J Clin Oncol. 2009;27 (suppl; abstr 4016).
15. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the
PI3K pathway. Cancer Cell. 2007;12:104-107.
16. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity
of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas
and their corresponding metastases. Clin Cancer Res. 2010;16:790-799.
17. Altomare I, Russell KB, Uronis HE, et al. Phase II trial of bevacizumab
(B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
J Clin Oncol. 2010;28 (suppl; abstr 3535).
18. Bendell JC, Nemunaitis J, Vukelja SJ, et al. Randomized placebocontrolled
phase II trial of perifosine plus capecitabine as second- or third-line
therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2011;29:
4394-4400.
19. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is
associated with advanced stage colorectal cancer and liver metastases. Cancer
Lett. 2008;265:258-269.
20. Takeuchi H, Kim J, Fujimoto A, et al. HGF activation in colorectal
cancer via c-met receptor regulates IAP proteins. Presented at: 98th Annual
Meeting of the American Association for Cancer Research; April 2007; Los
Angeles, CA.
21. Ding S, Merkulova-Rainon T, Han ZC, et al. HGF receptor upregulation
contributes to the angiogenic phenotype of human endothelial cells
and promotes angiogenesis in vitro. Blood. 2003;101:4816-4822.
22. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from
OAM4558g, a randomized phase II study evaluating MetMAb or placebo in
combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011;29 (suppl;
abstr 7505).
23. Eng C, Eng C, Bendell JC, et al. Phase I results of the randomized,
placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197,
irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT)
KRAS metastatic colorectal cancer (mCRC) who have received front-line
systemic therapy. Presented at: Gastrointestinal Cancers Symposium; January
2011; San Francisco, CA.
24. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report:
evaluating the clinical utility of tumor markers in oncology. J Natl Compr
Canc Netw. 2011;5:S1-S32.
25. Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and predictive
biomarkers in resected colon cancer: Current status and future perspectives
for integrating genomics into biomarker discovery. Oncologist. 2010;15:390-
404.
26. Khleif, SN, Doroshow JH, Hait WN, et al. AACR-FDA-NCI Cancer
Biomarkers Collaborative consensus report: advancing the use of biomarkers
in cancer drug development. Clinical Cancer Res. 2010;16:3299-3318.
200
VENOOK, BENDELL, AND WARREN
27. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response
to chemotherapy in colorectal cancer. Cancer J. 2011;17:114-126.
28. Maughan TS, Adams R, Smith CG, et al. Identification of potentially
responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine
chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature
results of the MRC COIN trial. J Clin Oncol. 2010;28 (suppl; abstr 3502).
29. Tveit K, Guren B, Glimelius P, et al. Randomized phase III study of
5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with
or without cetuximab, as first-line treatment of metastatic colorectal cancer:
the Nordic VII study (NCT00145314), by the Nordic Colorectal Cancer
Biomodulation Group. Ann. Oncol. 2010;21:viii9 (suppl; abstr LBA.20).
30. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of
chemotherapy, bevacizumab, and panitumumab compared with chemotherapy
and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol.
2009;27:672-680.
31. Tol J, Koopman. M, Cats M, et al. Chemotherapy, bevacizumab, and
cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-572.
32. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and
molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin
Oncol. 2004;22:1564-1571.
33. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival
prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526-3535.
34. Arango D, Laiho P, Kokko A, et al. Gene-expression profiling predicts
recurrence in Dukes’ C colorectal cancer. Gastroenterology, 2005;129:874-
884.
35. Barrier A, Boelle PV, Roser R, et al. Stage II colon cancer prognosis
prediction by tumor gene expression profiling. J Clin Oncol. 2006;24:4685-
4691.
36. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative
multigene reverse transcriptase-polymerase chain reaction assay for assessment
of recurrence risk in patients with stage II colon cancer. J Clin Oncol.
2011;29:4611-4619.
37. Clark-Langone KM, Sangli C, Krishnakumar J, et al. Translating
tumor biology into personalized treatment planning: Analytical performance
characteristics of the Oncotype DX Colon Cancer Assay. BMC Genomics.
2007;8:279.
38. O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor
gene expression and recurrence in four independent studies of patients with
stage II/III colon cancer treated with surgery alone or surgery plus adjuvant
fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937-3944.
39. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent
validation of a prognostic assay for stage II colon cancer using formalin-fixed
paraffin-embedded tissue. J Clin Oncol. 2011;29:4620-4626.
40. Salazar R, Roepman P, Capella G, et al. Gene expression signature to
improve prognosis prediction of stage II and III colorectal cancer. J Clin
Oncol. 2011;29:17-24.
41. Tan IB, Tan P. Genetics: an 18-gene signature (ColoPrint) for colon
cancer prognosis. Nat Rev Clin Oncol. 2011;8:131-133.
42. Robles A, Harris CC. Clinical outcomes and correlates of TP53 mutations
and cancer. Cold Spring Harb Perspect Biol. 2010;2:a001016.
43. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus
leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant
treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol.
2007;25:3456-3461.
44. Van Schaeybroeck S, Allen W, Turkington, RC, et al. Implementing
prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin
Oncol. 2011;8:222-232.
45. Tabernero J, Baselga J. Multigene assays to improve assessment of
recurrence risk and benefit from chemotherapy in early-stage colon cancer:
has the time finally arrived, or are we still stage locked? J Clin Oncol.
2010;28:3904-3907.
46. Arteaga CL, Baselga J. Impact of genomics on personalized cancer
medicine. Clin Cancer Res. 2012;18:612-618.
47. Engstrom PF, Bloom MG, Demetri GD, et al. NCCN molecular testing
white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc
Netw. 2011;6:S1-S16.
48. Wistuba II, Gelovani JG, Jacoby JJ, et al. Methodological and practical
challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011;8:135-
141.
49. Wu W, Shi Q, Sargent DJ. Statistical considerations for the next
generation of clinical trials. Semin Oncol 2011;38:598-604.
50. McClellan M, Benner J, Schilsky R, et al. An accelerated pathway for
targeted cancer therapies. Nat Rev Drug Discov. 2011;10:79-80.